Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer
- 1 January 2015
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 16 (1) , 33-39
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinibLung Cancer, 2013
- Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?Clinical Pharmacology & Therapeutics, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Erlotinib and pantoprazole: a relevant interaction or not?British Journal of Clinical Pharmacology, 2010
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyThe Lancet Oncology, 2010
- Effect of Proton Pump Inhibitors on Gastric Juice Volume, Gastric pH and Gastric Intramucosal pH in Critically Ill PatientsClinical Drug Investigation, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Efficacy and Safety of Pantoprazole versus Ranitidine in the Treatment of Patients with Symptomatic Gastroesophageal Reflux DiseaseDigestion, 2004